Nilotinib Hydrochloride Dihydrate Clonmel (Nilotinib)

Nilotinib targets the BCR‑ABL tyrosine‑kinase pathway, providing targeted therapy for specific hematologic malignancies.

• Chronic myeloid leukemia (chronic phase): restores normal blood counts and reduces disease‑specific genetic markers.
• Philadelphia chromosome‑positive acute lymphoblastic leukemia: offers a molecularly directed option to improve remission rates.
• Chronic myeloid leukemia (accelerated phase, when approved): helps achieve cytogenetic and molecular responses in later disease stages.

• Nilotinib binds to the ATP‑binding site of the BCR‑ABL fusion protein, inhibiting its tyrosine‑kinase activity. This blockade prevents downstream signaling that drives uncontrolled proliferation of malignant leukemic cells, leading to cell cycle arrest and apoptosis of the abnormal clone while sparing most normal cells.

Nilotinib may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects

• Nausea: mild to moderate gastrointestinal upset.
• Diarrhea: watery stools, often transient.
• Rash: maculopapular skin eruptions.
• Elevated liver enzymes: increased ALT/AST levels.
• Fatigue: generalized tiredness.
• Myalgia: muscle aches.

Serious or Rare Side Effects

• Cardiovascular events: myocardial infarction, arterial occlusion.
• Pancreatitis: abdominal pain with elevated amylase/lipase.
• Severe hepatic injury: jaundice, hepatic failure.
• QT interval prolongation: risk of arrhythmia.
• Severe skin reactions: Stevens‑Johnson syndrome, toxic epidermal necrolysis.

Before initiating therapy, clinicians should assess baseline organ function and cardiovascular risk.

• Baseline labs: obtain complete blood count, liver function tests, and serum electrolytes.
• Cardiac assessment: evaluate ECG and history of ischemic disease.
• Drug interactions: review concomitant medications that affect CYP3A4.
• Pregnancy and lactation: avoid use; discuss contraception with women of childbearing potential.
• Monitoring: schedule regular labs to detect hepatotoxicity and QT prolongation.
• Store at ambient temperature: keep below 25 °C in the original container, protect from moisture and direct sunlight.

Nilotinib is metabolized primarily by CYP3A4, making it susceptible to drug‑drug interactions.

Major Interactions (Avoid)

• Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): may markedly reduce nilotinib exposure.
• Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): can increase plasma concentrations and toxicity.

Moderate Interactions (Monitor Closely)

• Antacids containing aluminum or magnesium: may decrease absorption; separate dosing by at least 2 hours.
• Proton‑pump inhibitors: may modestly reduce bioavailability.
• Statins metabolized by CYP3A4 (e.g., simvastatin): increase risk of myopathy; consider dose adjustment.
• QT‑prolonging agents (e.g., fluoroquinolones): monitor ECG for additive effects.